-
Tytuł:
-
Effect of Helicobacter pylori Treatment on Long-term Mortality in Patients with Hypertension.
-
Autorzy:
-
Kim YI; Center for Gastric Cancer, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Kim YA; Cancer Survivorship Branch, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
Lee JW; College of Korean Medicine, Dongguk University, Gyeongju, Korea.
Kim HJ; Department of Cardiology, Center for Clinical Specialty, National Cancer Center, Goyang, Korea.
Kim SH; Department of Neurology, Research Institute and Hospital, National Cancer Center, Goyang, Korea.
Kim SG; Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea.
Kim JI; Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Kim JJ; Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Choi IJ; Center for Gastric Cancer, National Cancer Control Institute, National Cancer Center, Goyang, Korea.
-
Źródło:
-
Gut and liver [Gut Liver] 2020 Jan 15; Vol. 14 (1), pp. 47-56.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Original Publication: Seoul : Editorial Office of Gut and Liver
-
MeSH Terms:
-
Helicobacter pylori*
Anti-Bacterial Agents/*therapeutic use
Helicobacter Infections/*mortality
Hypertension/*mortality
Adult ; Aged ; Aged, 80 and over ; Databases, Factual ; Female ; Helicobacter Infections/complications ; Helicobacter Infections/drug therapy ; Humans ; Hypertension/microbiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Proportional Hazards Models ; Republic of Korea/epidemiology ; Retrospective Studies ; Risk Factors ; Young Adult
-
References:
-
Int J Epidemiol. 2017 Apr 1;46(2):e15. (PMID: 26822938)
BMJ. 2014 Aug 19;349:g4930. (PMID: 25139799)
Cancer Res Treat. 2012 Dec;44(4):219-26. (PMID: 23341785)
Am J Epidemiol. 2011 Mar 15;173(6):676-82. (PMID: 21330339)
Int J Cardiol. 2015 Mar 1;182:459-65. (PMID: 25602299)
Gut. 2017 Jan;66(1):6-30. (PMID: 27707777)
J Am Coll Cardiol. 2015 Nov 17;66(20):2173-2184. (PMID: 26564594)
Am J Epidemiol. 2018 Apr 1;187(4):786-792. (PMID: 29036565)
Nat Rev Cancer. 2017 May;17(5):271-285. (PMID: 28303904)
N Engl J Med. 2018 Mar 22;378(12):1085-1095. (PMID: 29562147)
IARC Monogr Eval Carcinog Risks Hum. 1994;61:1-241. (PMID: 7715068)
BMJ. 2016 Jan 14;352:h6926. (PMID: 26768836)
Cardiovasc Diabetol. 2016 Sep 13;15(1):131. (PMID: 27618811)
Eur J Cancer. 2015 Nov;51(17):2655-64. (PMID: 26338196)
BMJ. 2006 Jan 7;332(7532):22-7. (PMID: 16339220)
Cardiology. 2008;111(4):280-7. (PMID: 18451646)
Cardiology. 2010;116(2):89-97. (PMID: 20523043)
Am J Gastroenterol. 2017 Feb;112(2):212-239. (PMID: 28071659)
Eur Heart J. 2017 Sep 7;38(34):2599-2607. (PMID: 28662568)
J Gastroenterol Hepatol. 2014;29(7):1371-86. (PMID: 24758240)
N Engl J Med. 2014 Nov 6;371(19):1765-7. (PMID: 25372084)
J Neurol. 2012 Dec;259(12):2527-37. (PMID: 22688569)
Br J Clin Pharmacol. 2016 Aug;82(2):512-21. (PMID: 27090996)
N Engl J Med. 2018 Feb 15;378(7):636-644. (PMID: 29443671)
BMJ. 2014 May 20;348:g3174. (PMID: 24846275)
Eur J Immunol. 2015 Jan;45(1):17-31. (PMID: 25328099)
J Stroke Cerebrovasc Dis. 2014 Oct;23(9):2233-9. (PMID: 25263434)
-
Contributed Indexing:
-
Keywords: Helicobacter pylori; Hypertension; Mortality
-
Substance Nomenclature:
-
0 (Anti-Bacterial Agents)
-
Entry Date(s):
-
Date Created: 20190413 Date Completed: 20201104 Latest Revision: 20221222
-
Update Code:
-
20240104
-
PubMed Central ID:
-
PMC6974335
-
DOI:
-
10.5009/gnl18510
-
PMID:
-
30974928
-
Background/Aims: A meta-analysis of randomized trials performed in healthy asymptomatic individuals suggested that overall mortality may increase after Helicobacter pylori eradication despite a significant decrease in the gastric cancer incidence and mortality rates. This retrospective population-based cohort study investigated if H. pylori treatment is associated with an increase in overall mortality in patients with hypertension. Methods: From the database of the Korean National Health Insurance Sample Cohort, we selected 198,487 patients treated for hypertension between 2002 and 2010. Those who received H. pylori treatment ( H. pylori treatment cohort, 5,541 patients) were matched to those who did not (nontreatment cohort, 11,082 patients) at the ratio of 1 to 2. The primary outcome was the risk of overall mortality. The secondary outcomes were the risks of mortality due to cardiovascular disease, cerebrovascular disease, and cancer. The outcomes were evaluated from 6 months after H. pylori treatment to December 2013. A Cox proportional hazard model was used to estimate the hazard ratios (HRs). Results: During a median follow-up period of 4.8 years, death from any cause was reported in 4.1% of the patients in the H. pylori treatment cohort and 5.5% of the patients in the nontreatment cohort. The adjusted HR (aHR) for overall mortality in the H. pylori treatment cohort was 0.70 (95% confidence interval [CI], 0.60 to 0.82; p<0.001). With regard to cause-specific mortality, compared with the nontreatment cohort, the H. pylori treatment cohort had a lower risk of mortality due to cerebrovascular disease (aHR, 0.46; 95% CI, 0.26 to 0.81; p=0.007). The risks of mortality due to cancer and cardiovascular disease were not different between the cohorts. Conclusions: H. pylori treatment is not associated with an increase in overall mortality in patients treated for hypertension.
Comment in: Gut Liver. 2020 Jan 15;14(1):1-2. (PMID: 31945813)
